Stock Details
TAK is Takeda Pharmaceutical Company Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 13.32$. Average daily volumn in 3 months 3.09M. Market cap 46.23B



Stock symbol : TAK. Exchange : NYSE. Currency : USD
Lastest price : 14.87$. Total volume : 2.23M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Takeda Pharmaceutical Company Limited (TAK)
Last Price
14.87$
Change
0.14
Volume
2.23M

Previous Close14.73
Open14.84
Day Range14.76-14.93
Bid0.00 x 1.3k
Ask0.00 x 1.1k
Volume2.23M
Average Volume3.09M
Market Cap46.23B
Beta0.75
52 Week Range12.28-15.36
Trailing P/E30.35
Foward P/E7.51
Dividend (Yield %)5.00%
Ex-Dividend Date2022-03-30



Financial Details


According to Takeda Pharmaceutical Company Limited's financial reports the company's revenue in 2022 were 3.57T an increase(0%) over the years 2021 revenue that were of 3.2T. In 2022 the company's total earnings were 230.06B while total earnings in 2021 were 376B(-38.83%).


Loading ...



Organization

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynov... ate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Market Cap:
46.23B
Revenue:
3.57T
Total Assets:
13.18T
Total Cash:
849.7B



News about "Takeda Pharmaceutical Company Limited"

Takeda Pharmaceutical Co. Ltd. ADR

Source from : Wall Street Journal - 6 days ago

1 Day TAK 1.53% DJIA 0.45% S&P 500 -0.03% Health Care/Life Sciences 0.31% Christophe Weber President, CEO & Representative Director Takeda Pharmaceutical Co., Ltd. Constantine Saroukos Chief ...See details»


Takeda Pharmaceutical Company Limited (4502.T)

Source from : Yahoo Finance - 10 days ago

The FDA has accepted and granted priority review to Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Biologics License Application (BLA) for TAK-003, the company's investigational dengue vaccine candidate.See details»


Thinking Of Investing In Takeda Pharmaceutical Company Limited (NYSE: TAK) Stock? Read This First

Source from : stocksregister - 14 days ago

Takeda Pharmaceutical Company Limited (NYSE:TAK) shares, rose in value on Thursday, November 17, with the stock price up by 0.69% to the previous dayโ€™s close as strong demand from buyers drove the ...See details»


takedas-dengue-vaccine-candidate-under-fda-priority-review-image

Takeda's Dengue Vaccine Candidate Under FDA Priority Review

Source from : YAHOO!Finance - 9 days ago

The FDA has accepted and granted priority review to Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Biologics License Application (BLA) for TAK-003, the company's investigational dengue vaccine candidate.See details»


takeda-pharmaceutical-company-limited-tak-upgraded-issued-by-wall-street-gurus-image

Takeda Pharmaceutical Company Limited (TAK) upgraded Issued by Wall Street Gurus

Source from : newsheater - 10 month ago

Takeda Pharmaceutical Company Limited (NYSE:TAK) went up by 1.14% from its latest closing price compared to the recent 1-year high of $15.36. The companyโ€™s stock price has collected 3.49% of gains in ...See details»


We Analyzed the Future Direction of Takeda Pharmaceutical Company Limited (TAK), Here is What We Found

Source from : newsheater - 1 year ago

Takeda Pharmaceutical Company Limited (NYSE:TAK) went up by 1.53% from its latest closing price compared to the recent 1-year high of $15.36. The companyโ€™s stock price has collected 4.67% of gains in ...See details»


Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

Source from : Stockhouse - 9 days ago

For the purposes of this notice, โ€œpress release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or ...See details»


Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Source from : Nasdaq - 2 years ago

Please note that the dividend history might include the companyโ€™s preferred securities as well. Price/Earnings Ratio is a widely used stock evaluation measure. For a security, the Price ...See details»


Federal Lawsuit Funded by We The Patriots USA Filed Against Takeda Pharmaceuticals

Source from : Digital Journal - 14 days ago

A federal lawsuit was filed today in the U.S. District Court of Massachusetts against Takeda ... the pharma giant unlawfully denied their requests for a religious exemption to the company ...See details»


Takeda Receives Prestigious Prix Galien Canada Innovative Product Award for TAKHZYROยฎ (lanadelumab)

Source from : Benzinga.com - 11 days ago

Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited ((TAK), a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to ...See details»


Takeda Pharmaceutical Company Limited (TAK)

Source from : Yahoo Finance - 15 days ago

The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical ...See details»


Takeda : FDA Grants Priority Review Of BLA For Dengue Vaccine Candidate TAK-003

Source from : Business Insider - 9 days ago

(RTTNews) - Takeda (TAK) said that the U.S. Food and Drug Administration has granted priority review of the Biologics License Application for TAK-003, the company's investigational dengue vaccine ...See details»


Takeda's Iclusig beats Novartis Glivec in phase 3 leukemia trial

Source from : Seeking Alpha - 14 days ago

Takeda Pharmaceutical (NYSE ... as reported in literature. The company noted that PhALLCON is the first global, phase 3 head-to-head trial comparing two tyrosine kinase inhibitors (TKIs) as ...See details»


Japan's Takeda Pharma raises annual profit forecast on weak yen

Source from : Channel NewsAsia Singapore - 1 month ago

TOKYO : Takeda Pharmaceutical Co raised its full-year ... Japan's biggest drugmaker to buy in-development treatments. The company, which makes more than 80 per cent of its sales outside Japan ...See details»